3951-89-1

Usage

Uses

As the applications and potential uses of 7-Bromo-1,2,3,4-tetrahydro-benzo[b]azepin-5-one are not widely documented in current scientific literature, it is difficult to provide a comprehensive list of its uses. However, based on its chemical structure and the properties of similar benzazepine compounds, it can be inferred that it may have potential applications in various fields, such as:
Used in Pharmaceutical Industry:
7-Bromo-1,2,3,4-tetrahydro-benzo[b]azepin-5-one may be used as a chemical intermediate or a building block for the synthesis of more complex molecules with potential pharmaceutical applications. Its unique structure, including the bromine atom, could be exploited to create new drugs with specific therapeutic effects.
Used in Chemical Research:
7-Bromo-1,2,3,4-tetrahydro-benzo[b]azepin-5-one could be used as a research compound in the field of organic chemistry, particularly in the study of benzazepine derivatives and their potential applications. Its synthesis, reactivity, and interactions with other molecules could provide valuable insights into the development of new chemical processes and compounds.
Used in Material Science:
The unique structure of 7-Bromo-1,2,3,4-tetrahydro-benzo[b]azepin-5-one may also make it a candidate for use in the development of new materials with specific properties, such as improved stability, conductivity, or other characteristics. Its potential applications in material science could be explored further through research and development efforts.

Upstream product

• 872624-49-2 (+/-)-1-isopropyl-4-methyl-7-bromo-5-oxo-2,3,4,5-tetrahydrobenzo[b]azepine-1,4-dicarboxylate 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 223526-84-9 methyl 5-bromo-2-{[(4-methylphenyl)sulfonyl]amino}benzoate 

Downstream Products

• 313724-26-4 7-bromo-1-(t-butoxycarbonyl)-1,2,3,4-tetrahydro-1-benzazepin-5-one 
• 313740-83-9 7-{4-[2-(butoxy)ethoxy]phenyl}-N-(4-{[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-propyl-2,3-dihydro-1H-1-benzazepine-4-carboxamide 
• 313738-91-9 7-[4-(2-butoxyethoxy)phenyl]-1-propyl-2,3,4,5-tetrahydro-1H-1-benzazepine-5-one 
• 313738-96-4 7-{4-[2-(butoxy)ethoxy]phenyl}-1-propyl-2,3-dihydro-1H-1-benzazepine-4-carboxylic acid 
• 739355-72-7 7-{4-[2-(butoxy)ethoxy]phenyl}-1-cyclobutylmethyl-N-(4-{[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-2,3-dihydro-1H-1-benzazepine-4-carboxamide 
• 719297-15-1 methyl 7-{4-[2-(butoxy)ethoxy]phenyl}-1-[(1-methyl-1H-imidazol-2-yl)methyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylate 
• 719297-16-2 methyl 7-{4-[2-(butoxy)ethoxy]phenyl}-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylate 
• 313753-40-1 methyl 7-{4-[2-(butoxy)ethoxy]phenyl}-1-[(1-methyl-1H-pyrazol-5-yl)methyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylate 
• 313752-00-0 7-{4-[2-(butoxy)ethoxy]phenyl}-1-[(1-methyl-1H-pyrazol-5-yl)methyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylic acid 
• 313751-95-0 7-{4-[2-(butoxy)ethoxy]phenyl}-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylic acid 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

Orally active CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety

The search for orally active CCR5 antagonists was performed by chemical modification of the 1-benzothiepine 1,1-dioxide 3 and 1-benzazepine 4 lead compounds containing a tertiary amine moiety. Replacement of methyl group with a 2-(C2-4 alkoxy)ethoxy group at the 4-position on the 7-phenyl group of the 1-benzothiepine ring resulted in both enhanced activity and significant improvement in the pharmacokinetic properties upon oral administration in rats. Introduction of C2-4 alkyl, phenyl or (hetero)arylmethyl groups as the 1-substituent on the 1-benzazepine ring together with the 2-(butoxy)ethoxy group led to further increase of activity. Among the 1- benzazepine derivatives, the isobutyl (6i), benzyl (6o) or 1-methylpyrazol-4-ylmethyl (6s) compounds were found to exhibit highly potent inhibitory effects, equivalent to the injectable CCR5 antagonist 1, in the HIV-1 envelopemediated membrane fusion assay. In particular, compound 6s showed the most potent CCR5 antagonistic activity (IC50=2.7 nM) and inhibitory effect (IC50=1.2 nM) on membrane fusion, together with good pharmacokinetic properties in rats. The synthesis of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives and their biological activity are described.

BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

Compounds of the general formula (I): or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R1 is a 5- to 6-membered aromatic ring which bears a substituent represented by the general formula: R-Z1-X-Z2- (wherein R1 is hydrogen or optionally substituted hydrocarbyl; X is optionally substituted alkylene; and Z1 and Z2 are each a heteroatom) and may be further substituted, with R being optionally bonded to the aromatic ring to form another ring; Y is optionally substituted imino; and R2 and R3 are each optionally substituted aliphatic hydrocarbyl or an optionally substituted hetero-alicyclic group.